Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 14, 2020, titled "Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India".